Myocardial fatty acid metabolism and cardiac performance in heart failure

Nuutila P, Koivisto VA, Knuuti J, et al.: Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992, 89:1767–1774. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785–789. Kates AM, Herrero P, Dence C, et al.: Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003, 41:293–299. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005, 85:1093–1129. Sardanelli F, Quarenghi M: MR spectroscopy of the heart. Radiol Med (Torino) 2006, 111:1025–1034. Takala TO, Nuutila P, Pulkki K, et al.: 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med Mol Imaging 2002, 29:1617–1622. Schelbert H, Schwaiger M: PET studies of the heart. In Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. Edited by Phelps M, Marizziotta J, Schelbert H. New York: Raven Press; 1986:599–616. Bergmann SR: Imaging of myocardial fatty acid metabolism with PET. J Nucl Cardiol 2007, 14(3 Suppl):S118–S124. Bergmann SR, Weinheimer CJ, Markham J, Herrero P: Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996, 37:1723–1730. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G: Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991, 122:795–801. Neubauer S: The failing heart—an engine out of fuel. N Engl J Med 2007, 356:1140–1151. Neubauer S, Horn M, Cramer M, et al.: Myocardial phospho-creatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190–2196. Recchia FA, McConnell PI, Bernstein RD, et al.: Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998, 83:969–979. Osorio JC, Stanley WC, Linke A, et al.: Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002, 106:606–612. Nikolaidis LA, Sturzu A, Stolarski C, et al.: The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004, 61:297–306. Augustus AS, Buchanan J, Park TS, et al.: Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006, 281:8716–8723. Paolisso G, Gambardella A, Galzerano D, et al.: Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994, 43:174–179. Lommi J, Kupari M, Yki-Jarvinen H: Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998, 81:45–50. Norrelund H, Wiggers H, Halbirk M, et al.: Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 2006, 260:11–21. Taylor M, Wallhaus TR, Degrado TR, et al.: An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 2001, 42:55–62. Davila-Roman VG, Vedala G, Herrero P, et al.: Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002, 40:271–277. Tuunanen H, Engblom E, Naum A, et al.: Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006, 12:644–652. Chandler MP, Kerner J, Huang H, et al.: Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004, 287:H1538–H1543. Lei B, Lionetti V, Young ME, et al.: Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 2004, 36:567–576. Sack MN, Rader TA, Park S, et al.: Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837–2842. Razeghi P, Young ME, Alcorn JL, et al.: Metabolic gene expression in fetal and failing human heart. Circulation 2001, 104:2923–2931. Martin MA, Gomez MA, Guillen F, et al.: Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 2000, 1502:330–336. An D, Rodrigues B: Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006, 291:H1489–H1506. Buchanan J, Mazumder PK, Hu P, et al.: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341–5349. Knuuti J, Takala TO, Nagren K, et al.: Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 2001, 44:184–187. Turpeinen AK, Takala TO, Nuutila P, et al.: Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Diabetes 1999, 48:1245–1250. Peterson LR, Herrero P, Schechtman KB, et al.: Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191–2196. Myrmel T, Forsdahl K, Larsen TS: Triacylglycerol metabolism in hypoxic, glucose-deprived rat cardiomyocytes. J Mol Cell Cardiol 1992, 24:855–868. Morrow DA, Givertz MM: Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005, 112:3218–3221. Korvald C, Elvenes OP, Myrmel T: Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000, 278:H1345–H1351. Liu Q, Docherty JC, Rendell JC, et al.: High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002, 39:718–725. Xu KY, Zweier JL, Becker LC: Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport. Circ Res 1995, 77:88–97. Chandler MP, Stanley WC, Morita H, et al.: Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002, 91:278–280. Sabbah HN, Chandler MP, Mishima T, et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002, 8:416–422. Nikolaidis LA, Elahi D, Hentosz T, et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955–961. Bersin RM, Wolfe C, Kwasman M, et al.: Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994, 23:1617–1624. Hermann HP, Pieske B, Schwarzmuller E, et al.: Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999, 353:1321–1323. Hermann HP, Arp J, Pieske B, et al.: Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 2004, 6:213–218. Cottin Y, Lhuillier I, Gilson L, et al.: Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail 2002, 4:181–184. Feola M, Biggi A, Francini A, et al.: The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischaemic ventricular dysfunction. Int J Cardiovasc Imaging 2004, 20:315–320. Wiggers H, Norrelund H, Nielsen SS, et al.: Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. Am J Physiol Heart Circ Physiol 2005, 289:H938–H946. Tuunanen H, Engblom E, Naum A, et al.: Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114:2130–2137. Brottier L, Barat JL, Combe C, et al.: Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990, 11:207–212. Belardinelli R, Purcaro A: Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001, 22:2164–2170. Fragasso G, Palloshi A, Puccetti P, et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48:992–998. Fragasso G, Perseghin G, De Cobelli F, et al.: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006, 27:942–948. Rosano GM, Vitale C, Sposato B, et al.: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003, 2:16. Vitale C, Wajngaten M, Sposato B, et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004, 25:1814–1821. Di Napoli P, Taccardi AA, Barsotti A: Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005, 91:161–165. Fragasso G, Piatti Md PM, Monti L, et al.: Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003, 146:E18. El-Kady T, El-Sabban K, Gabaly M, et al.: Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005, 5:271–278. Schmidt-Schweda S, Holubarsch C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000, 99:27–35. Lee L, Campbell R, Scheuermann-Freestone M, et al.: Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280–3288. Monti LD, Setola E, Fragasso G, et al.: Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006, 290:E54–E59. Mody FV, Singh BN, Mohiuddin IH, et al.: Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998, 82:42K–49K.